Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 233 ()
DOP41 Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study

ECCO'20 Vienna

Year: 2020
Authors:

M. Kabir1,2, K. Curtius3, I. Al-Bakir2,3,4, J. Hartono5, M. Johnson6, J.E. East6, J.O. Lindsay7,8, R. Vega9, S. Thomas-Gibson1,2, A. Hart2,4, T. Graham3, A. Wilson1,2

1Wolfson Endoscopy Unit, St Mark’s Hospital, London, UK, 2Division of Surgery and Cancer, Imperial College London, London, UK, 3Barts Cancer Institute, Queen Mary University of London, London, UK, 4Inflammatory Bowel Diseases Unit, St Mark’s Hospital, London, UK, 5Gastroenterology Department, National University Hospital, Singapore, 6Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK, 7Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK, 8Barts and the London School of Medicine and Dentistry, Centre for Immunobiology, Queen Mary University of London, London, UK, 9Endoscopy Unit, University College London Hospital, London, UK

DOP42 Impact of discontinuing thiopurines at anti-TNF initiation in inflammatory bowel disease: A nationwide Danish cohort study

ECCO'20 Vienna

Year: 2020
Authors:

S. Bohn Thomsen1, R. Ungaro2, K. Allin3, G. Poulsen1, A. Mikael1, J.F. Colombel2, T. Jess1

1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, 2Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA, 3Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

DOP43 The risk of extra-intestinal cancer in inflammatory bowel disease (IBD): A systematic review and meta-analysis of population-based cohort studies

ECCO'20 Vienna

Year: 2020
Authors:

B.Z.S. Lo, M. Zhao, I. Vind, J. Burisch

Copenhagen University Hospital Hvidovre, The Gastrounit, Hvidovre, Denmark

DOP44 Cancer risk in a high-incidence inflammatory bowel disease population: a Faroese IBD cohort study

ECCO'20 Vienna

Year: 2020
Authors:

J.M.M. Midjord1, A.G. Vang2, T. Hammer3, J. Burisch1, K.R. Nielsen1, The Faroese IBD Study Group

1Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands, 2Department of Health and Nursing Sciences, University of the Faroe Islands, Torshavn, Faroe Islands, 3Department of Occupational Medicine and Public Health, The Faroese Hospital System, Torshavn, Faroe Islands

DOP45 Increased prevalence but not incidence of myocardial infarction and stroke in patients with inflammatory bowel diseases in Quebec in 1996–2015

ECCO'20 Vienna

Year: 2020
Authors:

C. Verdon1, J. Reinglas1, C. Filliter1, J. Coulombe1, L. Gonczi2, W. Afif1, G. Wild1, E. Seidman1, A. Bitton1, T. Bessissow1, P. Brassard1, P.L. Lakatos PhD1,2

1Division of Gastroenterology, McGill University, Montreal, Canada, 2Department of Medicine I, Semmelweis University, Budapest, Hungary

DOP46 Impact of a genetic burden on familial aggregation of inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

H.S. Lee1,2, L. Hannes1, M. Vancamelbeke3, V. Ballet4, M. Ferrante3,4, S. Vermeire3,4, I. Cleynen1

1Laboratory of Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, 2Department of Biochemistry and Molecular Biology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Republic of, 3Department Chronic Diseases Metabolism and Ageing CHROMETA, Translational Research Center for Gastrointestinal Disorders TARGID, KU Leuven, Leuven, Belgium, 4Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

DOP47 The changing pattern of inflammatory bowel disease incidence in Northern France: A continuing increase in the young women (1988–2014)

ECCO'20 Vienna

Year: 2020
Authors:

T. CRETIN1, H. Sarter2, G. Savoye3, M. Fumery4, A. Leroyer2, L. Dauchet2, B. Pariente5, C. Gower-Rousseau2

1Hôpital Saint Philibert, Pathologie Digestive, Lomme, France, 2Epimad Registry- Maison de la Recherche CHU Lille, Public Health- Epidemiology, Lille, France, 3CHU Rouen, Service d’Hépato-Gastroentérologie et Oncologie Digestive, Rouen, France, 4CHU Amiens, Service d’Hépato-Gastroentérologie, Amiens, France, 5Hôpital Huriez- CHU Lille, Maladies de l’Appareil Digestif, Lille, France

DOP48 Gene expression landscape of epithelial monolayer in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

S. Sæterstad1, A.E. Østvik2,3, A.K. Sandvik1,2,3, A. Granlund Van Beelen1

1Centre of Molecular Inflammation Research, Norwegian University of Science and Technology NTNU, Trondheim, Norway, 2Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology NTNU,Trondheim, Norway, 3Department of Gastroenterology, St. Olav’s University Hospital, Trondheim, Norway

DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive Escherichia coli

ECCO'20 Vienna

Year: 2020
Authors:

C. Douadi1, E. Vazeille1, C. Chambon2, M. Hébraud3, M. Dodel4, B. Pereira4, D. Coban4, A. Buisson4, N. Barnich1

1Clermont-Auvergne University, M2iSH Laboratory, Clermont-Ferrand, France, 2INRA, Plateforme d’Exploration du Métabolisme- Composante Protéomique PFEMcp, Saint-Genès-Champanelle, France, 3INRA, UMR Microbiologie Environnement Digestif Santé MEDiS, Saint-Genès-Champanelle, France, 4CHU, Gastro-entérologie, Clermont-Ferrand, France

DOP50 The landscape of somatic mutations in non-neoplastic IBD-affected colon

ECCO'20 Vienna

Year: 2020
Authors:

S. Olafsson1, R.E. McIntyre1, T. Coorens2, T. Butler2, P. Robinson2, H. Lee-Six2, M. Sanders2, K. Arestang3, C. Dawson3, M. Tripathi4, K. Strongili3, Y. Hooks2, M.R. Stratton2, M. Parkes3, I. Martincorena2, T. Raine3, P.J. Campbell2, C.A. Anderson1

1Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, UK, 2Cancer, Aging and Somatic Mutations, Wellcome Trust Sanger Institute, Hinxton, UK, 3Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge, UK, 4Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

DOP51 Investigation on the role of Par4-associated cell polarity and associated barrier defects in inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

F. Branchi, C. Heldt, B. Siegmund, M. Schumann

Charité Universitätsmedizin Berlin – Campus Benjamin Franklin, Berlin, Germany

DOP52 The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s disease or ulcerative colitis reflects the respective disease

ECCO'20 Vienna

Year: 2020
Authors:

A. Unterweger1, J. Caesar1, P. Winkelmann1, A. Rüscher1, M. Seuß1, S. Breiteneicher5, J. Stallhofer5, F. Beigel5, M. Siebeck1, R. Gropp1

1Hospital of the Ludwig Maximilian Universität, General Visceral und Transplantation Surgery, München, Germany, 5Hospital of the Ludwig Maximilian Universität, Department of Medicine II, München, Germany

DOP53 PTPN2 and TiO2 in the pathogenesis of inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

J. Conde, M. Schwarzfischer, E. Katkeviciute, J. Häfliger, A. Niechcial, N. Brillant, K. Atrott, K. Bäbler, M. Scharl

Department of Gastroenterology and Hepatology, University Hospital Zurich, c/o University of Zurich, Zurich, Switzerland

DOP54 Integrated network analysis using patient-specific single-nucleotide polymorphism profiles uncovers new pathways involved in ulcerative colitis pathogenesis

ECCO'20 Vienna

Year: 2020
Authors:

D. Modos1,2,3, J. Brooks2,3,4, P. Sudhakar2,3,5, B. Verstockt5,6, B. Alexander-Dann1, A. Zoufir1, D. Fazekas2,7, S. Vermeire5,6, T. Korcsmaros2,3, A. Bender1

1Department of Chemistry, University of Cambridge, Cambridge, UK, 2Earlham Institute, Norwich, UK, 3Gut Microbes and Health Programme, Quadram Institute, Norwich, UK, 4Department of Gastroenterology, Norfolk and Norwich University Hospitals, Norwich, UK, 5Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, 6Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 7Department of Genetics, Eötvös Loránd University, Budapest, Hungary

DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE

ECCO'20 Vienna

Year: 2020
Authors:

G. Mantzaris1, B. Bressler2, U. Kopylov3, M. Bassel4, N. Brett4, C. Colby5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, A. Yarur12

1Department of Gastroenterology, Evangelismos Hospital, Athens, Greece, 2Department of Gastroenterology, St. Paul’s Hospital, Vancouver, Canada, 3Department of Gastroenterology, Sheba Medical Center, Tel Aviv, Israel, 4Evidera, Real-World Evidence, Montreal, Canada, 5Evidera, Real-World Evidence, San Francisco, USA, 6Department of Medical Affairs, Takeda Pharmaceuticals USA Inc., Deerfield, USA, 7Department of Medical Affairs, Takeda Canada Inc., Oakville, Canada, 8Department of Medical Affairs, Takeda Hellas S.A. Athens, Athens, Greece, 9Department of Global Medical Affairs, Takeda Pharmaceuticals International AG, Zurich, Switzerland, 10Evidence Generation and Publications, Takeda Pharmaceuticals International, Singapore, 11Global Outcomes Research, Takeda Pharmaceuticals International, Boston, USA, 12Department of Gastroenterology, Medical College of Wisconsin, Milwaukee, USA

DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension

ECCO'20 Vienna

Year: 2020
Authors:

W.J. Sandborn1, D.S. Rowbotham2, R.W.L. Leong3, C. Han4, Y. Zhou5, H. Zhang5, J. Johanns5, C. Marano6, S. Danese7, UNIFI Investigators

1Department of Gastroenterology, University of California San Diego, La Jolla, USA, 2Department of Gastroenterology and Hepatology, Auckland City Hospital, Auckland, New Zealand, 3Department of Gastroenterology, Concord and Macquarie University Hospitals, Sydney, Australia, 4Strategic Market Access, Janssen Global Services- LLC, Malvern, USA, 5Department of Clinical Biostats, Janssen Research and Development- LLC, Spring House, USA, 6Department of Immunology, Janssen Research and Development- LLC, Spring House, USA, 7Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy

DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study

ECCO'20 Vienna

Year: 2020
Authors:

N.A. Cohen1,2, N. Plevris3, U. Kopylov2,4, A. Grinman2,4, B. Ungar1,2, H. Yanai2,5, H. Leibovitzh2,5, N. Fliss1,2, A. Hirsch1,2, E. Ritter1,2, Y. Ron1,2, A. Bar-Gil Shitrit6,7, E. Goldin6,7, I. Dotan2,5, S. Ben-Horin2,4, C. Lees3,8, N. Maharshak1,2

1Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel, 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK, 4Department of Gastroenterology and Liver Diseases, Sheba Medical Center, Ramat Gan, Israel, 5IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikvah, Israel, 6Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel, 7Hadassah Medical School, Hebrew University of Jerusalem, Jerusalem, Israel, 8The University of Edinburgh, Western General Hospital Campus, Center for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK

DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study

ECCO'20 Vienna

Year: 2020
Authors:

V.B. Biemans1, J.A.M. Sleutjes2, A.C. de Vries2, A.G. Bodelier3, G. Dijkstra4, B. Oldenburg5, M. Löwenberg6, A.A. van Bodegraven7, A.E. van der Meulen-de Jong8, N.K. de Boer9, N. Srivastava10, R.L. West11, T. Römkens12, C.S. Horjus Talabur Horje13, J.M. Jansen14, J. Hoekstra3, R.K. Weersma4, F.D. van Schaik5, F. Hoentjen1, M.J. Pierik15, Dutch Initiative on Crohn and Colitis (ICC)

1Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands, 2Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands, 3Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, The Netherlands, 4Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands, 5Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands, 6Department of Gastroenterology and Hepatology, Amsterdam University Medical Center- AMC, Amsterdam, The Netherlands, 7Department of Gastroenterology and Hepatology, Zuyderland Medical Center, Sittard, The Netherlands, 8Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands, 9Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands, 10Department of Gastroenterology and Hepatology, Haaglanden Medical Center, Den Haag, The Netherlands, 11Department of Gastroenterology and Hepatology, Sint Franciscus Hospital, Rotterdam, The Netherlands, 12Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands, 13Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, The Netherlands, 14Department of Gastroenterology and Hepatology, OLVG Hospital, Amsterdam, The Netherlands, 15Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands

DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open

ECCO'20 Vienna

Year: 2020
Authors:

J.F. Colombel1, M.T. Osterman2, P. Ibanez3, A.J. Thorpe4, H. Zhang4, N. Lawendy4, C. Su4, W. Reinisch5

1Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA, 2Penn Presbyterian Medical Center, Philadelphia, PA, USA, 3Clínica Las Condes, Santiago, Chile, 4Pfizer Inc., Collegeville, PA, USA, 5Medical University of Vienna, Vienna, Austria

DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP)

ECCO'20 Vienna

Year: 2020
Authors:

S. Danese1, K. Subramanian2, J. Van Zyl3, S. Adsul4, D. Lindner5, J. Roth6, S. Vermeire7

1Department of Gastrointestinal Immunopathology, Humanitas University, Milan, Italy, 2Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australia, 3University of the Free State, Department of Gastroenterology, Bloemfontein- Free State, South Africa, 4Department of Global Medical Affairs, Takeda Pharmaceuticals International AG, Zurich, Switzerland, 5Statistical and Quantitative Sciences, Data Sciences Institute, Takeda Pharmaceuticals International AG, Zurich, Switzerland, 6Chief Medical Office, Global Medical Research, Takeda Pharmaceuticals International AG, Zurich, Switzerland, 7Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 233 ()